IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ImmunityBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$8.42−0.76 (-8.28%)
Close on Oct 19, 2026
- Market cap
- $8.84B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
19.1%
202M of 1.06B shares
Institutional holders
404
66 new, 44 sold out
Net institutional buying
24M
In Q2 2026
Insider trades, 12 months
0 buys · 14 sales
Net sold $8.39M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Patrick Soon-Shiong | 745,518,285 | 64.80% | 13D (active) amendment | Jul 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IBRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 34,083,262 | 3.22% | $298.40M | +7,736,819 | 0.00% |
| State Street Corp | 21,398,438 | 2.02% | $187.34M | +3,690,335 | 0.01% |
| Vanguard Portfolio Management LLC | 17,863,911 | 1.69% | $156.40M | +1,541,067 | 0.01% |
| Vanguard Capital Management LLC | 15,691,579 | 1.48% | $137.38M | +563,865 | 0.00% |
| D. E. Shaw & Co., Inc. | 11,551,019 | 1.09% | $101.13M | −1,020,578 | 0.05% |
| Two Sigma Investments, LP | 11,097,106 | 1.05% | $97.16M | +6,711,606 | 0.07% |
| Geode Capital Management, LLC | 9,847,896 | 0.93% | $86.23M | +1,815,975 | 0.00% |
| Millennium Management LLC | 5,579,793 | 0.53% | $48.85M | +4,159,549 | 0.02% |
| Northern Trust Corp | 3,565,248 | 0.34% | $31.21M | +1,060,467 | 0.00% |
| Morgan Stanley | 3,432,678 | 0.32% | $30.05M | −586,191 | 0.00% |
| Goldman Sachs Group Inc | 3,234,277 | 0.31% | $28.32M | −2,801 | 0.00% |
| UBS Group AG | 3,195,728 | 0.30% | $27.98M | +250,840 | 0.00% |
| Charles Schwab Investment Management Inc | 2,888,607 | 0.27% | $25.29M | +410,666 | 0.00% |
| Woodline Partners LP | 2,500,189 | 0.24% | $21.89M | −947,157 | 0.07% |
| SEB Asset Management AB | 2,447,150 | 0.23% | $21.42M | – | 0.08% |
| Vanguard Fiduciary Trust Co | 2,412,338 | 0.23% | $21.12M | +289,210 | 0.00% |
| Bank Of America Corp /De/ | 2,184,489 | 0.21% | $19.13M | −263,354 | 0.00% |
| Voloridge Investment Management, LLC | 1,721,902 | 0.16% | $15.08M | −1,205,650 | 0.06% |
| Federated Hermes, Inc. | 1,713,200 | 0.16% | $15.00M | +326,609 | 0.02% |
| Royal Bank of Canada | 1,542,717 | 0.15% | $13.51M | +56,668 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 404 | 202M | 19.1% | 66 / 143 | 101 / 44 | 42M | 19M |
| Q1 2026 | 386 | 179M | 16.9% | 145 / 137 | 60 / 32 | 80M | 38M |
| Q4 2025 | 278 | 170M | 16.0% | 46 / 99 | 68 / 28 | 41M | 15M |
| Q3 2025 | 264 | 144M | 13.6% | 49 / 94 | 56 / 23 | 40M | 21M |
| Q2 2025 | 242 | 125M | 11.8% | 61 / 102 | 38 / 27 | 49M | 3M |
| Q1 2025 | 211 | 80M | 7.5% | 45 / 76 | 40 / 33 | 11M | 14M |
| Q4 2024 | 202 | 83M | 7.8% | 44 / 71 | 41 / 20 | 22M | 9M |
| Q3 2024 | 182 | 70M | 6.6% | 24 / 63 | 42 / 32 | 23M | 4M |
| Q2 2024 | 194 | 63M | 5.9% | 51 / 63 | 46 / 21 | 11M | 15M |
| Q1 2024 | 166 | 69M | 6.5% | 35 / 51 | 42 / 16 | 13M | 3M |
| Q4 2023 | 148 | 60M | 5.6% | 30 / 58 | 27 / 13 | 17M | 7M |
| Q3 2023 | 132 | 50M | 4.7% | 29 / 33 | 31 / 11 | 12M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IBRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 12,496,050 | 1.18% | $109.40M | 1.02% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 11,597,491 | 1.09% | $101.54M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 9,922,040 | 0.94% | $86.87M | 0.10% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 8,399,273 | 0.79% | $73.54M | 0.04% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 4,852,894 | 0.46% | $42.49M | 0.09% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 4,224,658 | 0.40% | $30.29M | 0.09% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 3,725,546 | 0.35% | $32.62M | 0.03% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 3,568,391 | 0.34% | $31.24M | 0.20% | Jun 30, 2026 |
| iShares Biotechnology ETF | 2,665,564 | 0.25% | $23.34M | 0.26% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,579,769 | 0.15% | $11.88M | 0.03% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,515,884 | 0.14% | $11.40M | 0.07% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,465,790 | 0.14% | $11.02M | 0.05% | May 31, 2026 |
| Trenchless Fund ETF | 1,120,808 | 0.11% | $9.81M | 7.03% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 1,033,729 | 0.10% | $7.77M | 0.04% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 937,327 | 0.09% | $6.72M | 0.09% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Patrick Soon-Shiong | See remarks, Director, 10% owner | 299,383,725 | 28.25% | Apr 2, 2026 |
| Richard Adcock | CEO & President, Director | 562,274 | 0.05% | Feb 24, 2026 |
| David C. Sachs | Chief Financial Officer | 320,825 | 0.03% | Feb 24, 2026 |
| Regan J. Lauer | Chief Accounting Officer | 115,875 | 0.01% | Feb 24, 2026 |
| Christobel Selecky | Director | 159,478 | 0.02% | Jul 6, 2026 |
| Cheryl Cohen | Director | 256,596 | 0.02% | Jul 6, 2026 |
| Barry J. Simon | Director | 2,823,931 | 0.27% | Jun 26, 2026 |
| Linda Maxwell | Director | – | – | Jun 10, 2026 |
| Wesley Clark | Director | 8,000 | 0.00% | Jun 10, 2026 |
| Michael D. Blaszyk | Director | 265,582 | 0.03% | Jun 10, 2026 |
| Bruce Wendel | Director | – | – | Jun 10, 2026 |
| Nant Capital, LLC | 10% owner | 168,687,869 | 15.92% | Apr 2, 2026 |
| California Capital Equity, Llc | 10% owner | 321,767,183 | 30.36% | Apr 2, 2026 |
| MP 13 Ventures, LLC | 10% owner | 47,944,266 | 4.52% | Apr 2, 2026 |
| Cambridge Equities, LP | 10% owner | 29,369,076 | 2.77% | Apr 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cheryl Cohen Director | Jul 2, 2026 | Option exercise | +55,979 | $2.98 | $166.82K | 256,596 |
| Cheryl Cohen Director | Jul 2, 2026 | Sale(10b5-1 plan) | −131,210 | $9.50 | $1.25M | 125,386 |
| Christobel Selecky Director | Jul 1, 2026 | Option exercise | +124,414 | $2.99 | $372.00K | 159,478 |
| Christobel Selecky Director | Jul 1, 2026 | Sale(10b5-1 plan) | −159,478 | $9.02 | $1.44M | 0 |
| Christobel Selecky Director | Jul 1, 2026 | Option exercise | +35,064 | $2.98 | $104.49K | 35,064 |
| Christobel Selecky Director | Jun 30, 2026 | Option exercise | +700 | $2.98 | $2.09K | 700 |
| Christobel Selecky Director | Jun 30, 2026 | Option exercise | +300 | $2.99 | $897 | 1,000 |
| Christobel Selecky Director | Jun 30, 2026 | Sale(10b5-1 plan) | −1,000 | $9.00 | $9.00K | 0 |
| Christobel Selecky Director | Jun 29, 2026 | Sale(10b5-1 plan) | −95,722 | $9.01 | $862.46K | 0 |
| Christobel Selecky Director | Jun 29, 2026 | Option exercise | +30,000 | $2.84 | $85.20K | 95,722 |
| Christobel Selecky Director | Jun 29, 2026 | Option exercise | +33,549 | $2.99 | $100.31K | 65,722 |
| Christobel Selecky Director | Jun 29, 2026 | Option exercise | +32,173 | $2.98 | $95.88K | 32,173 |
| Barry J. Simon Director | Jun 24, 2026 | Sale(10b5-1 plan) | −25,000 | $7.88 | $197.00K | 2,802,788 |
| Barry J. Simon Director | Jun 4, 2026 | Sale(10b5-1 plan) | −23,033 | $7.18 | $165.38K | 2,827,788 |
| California Capital Equity, Llc 10% owner | Mar 31, 2026 | Conversion | +4,606,596 | $5.43 | $25.01M | 251,018,873 |
| Barry J. Simon Director | Feb 24, 2026 | Sale(10b5-1 plan) | −75,000 | $12.01 | $900.75K | 2,850,821 |
| Barry J. Simon Director | Feb 23, 2026 | Sale(10b5-1 plan) | −165,000 | $10.25 | $1.69M | 2,925,821 |
| Christobel Selecky Director | Feb 23, 2026 | Sale(10b5-1 plan) | −25,000 | $10.00 | $250.00K | 0 |
| Christobel Selecky Director | Feb 23, 2026 | Option exercise | +25,000 | $2.98 | $74.50K | 25,000 |
| Regan J. Lauer Chief Accounting Officer | Feb 22, 2026 | Tax withholding | −1,673 | $8.70 | $14.56K | 115,875 |
| Regan J. Lauer Chief Accounting Officer | Feb 22, 2026 | Option exercise | +4,065 | – | – | 117,548 |
| David C. Sachs Chief Financial Officer | Feb 22, 2026 | Option exercise | +40,650 | – | – | 320,825 |
| David C. Sachs Chief Financial Officer | Feb 22, 2026 | Tax withholding | −20,682 | $8.70 | $179.93K | 300,143 |
| Barry J. Simon Director | Feb 22, 2026 | Option exercise | +15,243 | – | – | 3,096,847 |
| Barry J. Simon Director | Feb 22, 2026 | Tax withholding | −6,026 | $8.70 | $52.43K | 3,090,821 |
| California Capital Equity, Llc 10% owner | Feb 22, 2026 | Option exercise | +114,329 | – | – | 29,816,081 |
| California Capital Equity, Llc 10% owner | Feb 22, 2026 | Tax withholding | −58,170 | $8.70 | $506.08K | 29,757,911 |
| Richard Adcock CEO & President, Director | Feb 22, 2026 | Tax withholding | −77,560 | $8.70 | $674.77K | 560,344 |
| Richard Adcock CEO & President, Director | Feb 22, 2026 | Option exercise | +152,439 | – | – | 637,904 |
| Barry J. Simon Director | Feb 20, 2026 | Sale(10b5-1 plan) | −10,000 | $9.25 | $92.50K | 3,081,604 |
| Richard Adcock CEO & President, Director | Feb 10, 2026 | Tax withholding | −140,048 | $6.93 | $970.53K | 485,465 |
| Richard Adcock CEO & President, Director | Feb 10, 2026 | Option exercise | +274,122 | – | – | 625,513 |
| David C. Sachs Chief Financial Officer | Feb 10, 2026 | Tax withholding | −42,643 | $6.93 | $295.52K | 280,175 |
| David C. Sachs Chief Financial Officer | Feb 10, 2026 | Option exercise | +82,236 | – | – | 322,818 |
| Regan J. Lauer Chief Accounting Officer | Feb 10, 2026 | Option exercise | +5,482 | – | – | 115,740 |
| Regan J. Lauer Chief Accounting Officer | Feb 10, 2026 | Tax withholding | −2,257 | $6.93 | $15.64K | 113,483 |
| Patrick Soon-Shiong See remarks, Director, 10% owner | Feb 10, 2026 | Tax withholding | −118,560 | $6.93 | $821.62K | 29,701,752 |
| Patrick Soon-Shiong See remarks, Director, 10% owner | Feb 10, 2026 | Option exercise | +274,122 | – | – | 29,820,312 |
| Barry J. Simon Director | Jan 20, 2026 | Sale(10b5-1 plan) | −76,967 | $6.54 | $503.36K | 3,166,604 |
| Barry J. Simon Director | Jan 20, 2026 | Sale(10b5-1 plan) | −75,000 | $7.88 | $591.00K | 3,091,604 |
| Christobel Selecky Director | Jan 20, 2026 | Sale(10b5-1 plan) | −25,000 | $7.51 | $187.75K | 0 |
| Christobel Selecky Director | Jan 20, 2026 | Option exercise | +25,000 | $2.98 | $74.50K | 25,000 |
| Christobel Selecky Director | Jan 16, 2026 | Sale(10b5-1 plan) | −50,000 | $5.00 | $250.00K | 0 |
| Christobel Selecky Director | Jan 16, 2026 | Option exercise | +50,000 | $2.98 | $149.00K | 50,000 |
| Richard Adcock CEO & President, Director | Dec 31, 2025 | Option exercise | +34,483 | – | – | 368,901 |
| Richard Adcock CEO & President, Director | Dec 31, 2025 | Tax withholding | −17,510 | $1.98 | $34.67K | 351,391 |
| David C. Sachs Chief Financial Officer | Dec 31, 2025 | Option exercise | +30,397 | – | – | 256,017 |
| David C. Sachs Chief Financial Officer | Dec 31, 2025 | Tax withholding | −15,435 | $1.98 | $30.56K | 240,582 |
| Barry J. Simon Director | Feb 22, 2025 | Tax withholding | −5,453 | $3.42 | $18.65K | 3,243,571 |
| Barry J. Simon Director | Feb 22, 2025 | Option exercise | +15,243 | – | – | 3,249,024 |
| Patrick Soon-Shiong See remarks, Director, 10% owner | Feb 22, 2025 | Tax withholding | −42,071 | $3.42 | $143.88K | 29,546,190 |
| Patrick Soon-Shiong See remarks, Director, 10% owner | Feb 22, 2025 | Option exercise | +114,329 | – | – | 29,588,261 |
| Regan J. Lauer Chief Accounting Officer | Feb 22, 2025 | Tax withholding | −1,669 | $3.42 | $5.71K | 110,258 |
| Regan J. Lauer Chief Accounting Officer | Feb 22, 2025 | Option exercise | +4,065 | – | – | 111,927 |
| David C. Sachs Chief Financial Officer | Feb 22, 2025 | Tax withholding | −15,860 | $3.42 | $54.24K | 225,620 |
| David C. Sachs Chief Financial Officer | Feb 22, 2025 | Option exercise | +40,650 | – | – | 241,480 |
| Richard Adcock CEO & President, Director | Feb 22, 2025 | Tax withholding | −78,167 | $3.42 | $267.33K | 334,418 |
| Richard Adcock CEO & President, Director | Feb 22, 2025 | Option exercise | +152,439 | – | – | 412,585 |
| Barry J. Simon Director | Jan 22, 2025 | Option exercise | +110,020 | $2.00 | $220.04K | 3,233,781 |
| David C. Sachs Chief Financial Officer | Dec 31, 2024 | Tax withholding | −15,405 | $2.56 | $39.44K | 200,830 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Barry J. Simon Officer, Director | Oct 5, 2026 | 560,000 | $7.66M | Oct 5, 2026 | OPEN MARKET |
| Cohen Cheryl Director | Oct 2, 2026 | 81,056 | $752.20K | Oct 2, 2026 | Exercise of Stock Options |
| L. Cohen Cheryl Officer | Jul 2, 2026 | 131,210 | $1.21M | Jul 2, 2026 | Exercise of Stock Options |
| Selecky Christobel Director | Jul 1, 2026 | 159,478 | $1.40M | Jul 1, 2026 | Exercise of Stock Options |
| Selecky Christobel Director | Jun 30, 2026 | 1,000 | $8.77K | Jun 30, 2026 | Exercise of Stock Options |
| Selecky Christobel Director | Jun 29, 2026 | 95,722 | $833.74K | Jun 29, 2026 | Exercise of Stock Options |
| Barry J. Simon Officer, Director | Jun 4, 2026 | 268,033 | $2.95M | Jun 4, 2026 | VARIOUS METHODS & DATES |
| Selecky Christobel Director | Feb 23, 2026 | 25,000 | $217.50K | Feb 23, 2026 | Exercise of Stock Options |
| Barry J. Simon Officer, Director | Jan 20, 2026 | 571,967 | $5.91M | Jan 20, 2026 | VARIOUS METHODS & DATES |
| Selecky Christobel Director | Jan 20, 2026 | 25,000 | $138.00K | Jan 20, 2026 | Exercise of Stock Options |
| Selecky Christobel Director | Jan 16, 2026 | 50,000 | $197.50K | Jan 16, 2026 | Exercise of Stock Options |